|
|
||||||||
J Thorac Cardiovasc Surg 2003;126:313-316
© 2003 The American Association for Thoracic Surgery
Editorial |
a the Departments of Cardiothoracic Surgery, The Cleveland Clinic Foundation, Cleveland, Ohio, USA
c Cardiovascular Medicine, The Cleveland Clinic Foundation, Cleveland, Ohio, USA
b Biostatistics, The Cleveland Clinic Foundation, Cleveland, Ohio, USA
Received for publication September 19, 2002; accepted for publication October 17, 2002.
* Address for reprints: A. Marc Gillinov, MD, Department of Thoracic and Cardiovascular Surgery, The Cleveland Clinic Foundation/F25, 9500 Euclid Ave, Cleveland, OH 44195 USA.
gillinom@ccf.org
| The first 300 words of the full text of this article appear below. |
"Mismatch can be considered to be present when the effective prosthetic valve area, after insertion into the patient, is less than that of a normal human valve...occasionally it can be a severe problem because the patient may be hemodynamically and symptomatically worse after valve replacement."
This is the definition of prosthesis-patient mismatch framed by Rahimtoola1 when he coined the term in 1978. Rahimtoola suggested that the degree of prosthesis-patient mismatch could be quantified and that such quantification might aid in identifying patients at risk of clinical sequelae caused by this condition. DeCarlo and colleagues2 seek to undertake these tasks in their report on small-sized Sorin Bicarbon prostheses (Sorin Biomedica, Saluggia, Italy). Although seemingly straightforward, application of Rahimtoolas definition requires examination and clarification of several complex concepts, including (1) measurement of prosthesis size, (2) measurement of patient size, (3) normalization of these values, (4) selection of referent values, and (5) assessment of the influence of prosthesis-patient size on clinical outcome.
Prosthesis Size
Prosthesis size can be based on either geometric dimensions or functional performance of the prosthesis (Table 1). Geometric expressions of prosthesis size include labeled size and internal orifice size. Functional expressions of prosthesis size include both in vitro and in vivo effective orifice area (EOA).
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |